Sandy Srinivas

Publications

• A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma. Harshman LC, Barbeau S, McMillian A, Srinivas S. Clin Genitourin Cancer. 2013; 11 (2): 100-6
• Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. J Clin Oncol. 2013; 31 (4): 412-9
• Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. J Clin Oncol. 2013; 31 (2): 181-6
• Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI. Urol Oncol. 2013; 31 (3): 379-85
• Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Clin Cancer Res. 2013; 19 (1): 215-24
• Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Lancet Oncol. 2012; 13 (9): 927-35
• Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. J Natl Compr Canc Netw. 2012; 10 (9): 1081-7
• Variations in normal serum alpha-fetoprotein (AFP) levels in patients with testicular cancer on surveillance. Patel P, Balise R, Srinivas S. Onkologie. 2012; 35 (10): 588-91
• mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. Cann GM, Gulzar ZG, Cooper S, Li R, Luo S, Tat M, Stuart S, Schroth G, Srinivas S, Ronaghi M, Brooks JD, Talasaz AH. PLoS One. 2012; 7 (11): e49144
• Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW. Urology. 2011; 78 (3): 626-30
• NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, KumarR, Margolin KA, Michaelson D, Motzer RJ, Pili P, Roethke S, Srinivas S. J Natl Compr Canc Network. 2011: 9 29
• Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Dreicer R, Garcia J, Hussain M, Rini B, Vogelzang N, Srinivas S, Somer B, Zhao YD, Kania M, Raghavan D. Invest New Drugs. 2011; 29 (6): 1441-8
• Pyoderma gangrenosum with the use of sunitinib. Nadauld LD, Miller MB, Srinivas S. J Clin Oncol. 2011; 29 (10): e266-7
• Toxicities of targeted agents in advanced renal cell carcinoma. Patel P, Srinivas S. Curr Clin Pharmacol. 2011; 6 (3): 181-8
• Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer Bazan JG, King CR, Brooks JD, Srinivas S. Open Prostate Cancer Journal. 2010: 3 99-104
• NCCN clinical practice guidelines in oncology: prostate cancer. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. J Natl Compr Canc Netw. 2010; 8 (2): 162-200
• Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. Clin Cancer Res. 2010; 16 (10): 2906-14
• Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI, Srinivas S. BJU Int. 2010; 106 (11): 1805-11
• The bevacizumab experience in advanced renal cell carcinoma. Harshman LC, Srinivas S. Onco Targets Ther. 2010: 3 179-89
• A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. Srinivas S, Harshman LC. Chemotherapy. 2009; 55 (5): 321-6
• A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Srinivas S, Feldman D. Anticancer Res. 2009; 29 (9): 3605-10
• Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer Krishnan AV, Srinivas S, Feldman D. Dermato Endocrinolgy. 2009: 1 7-11
• High dose chemotherapy followed by stem cell rescue for high risk germ cell tumors: the Stanford experience. Agarwal R, Dvorak CC, Stockerl- Goldstein KE, Johnson L, Srinivas S. Bone Marrow Transplant. 2009; 43 (7): 547-52
• Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. Harshman LC, Kuo CJ, Wong BY, Vogelzang NJ, Srinivas S. Cancer Invest. 2009; 27 (8): 851-6
• Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Krishnan AV, Srinivas S, Feldman D. Dermatoendocrinol. 2009; 1 (1): 7-11
• Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Harshman LC, Srinivas S, Kamaya A, Chung BI. Nat Rev Urol. 2009; 6 (6): 338-43
• Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ. J Clin Oncol. 2009; 27 (25): 4068-75
• Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Telli ML, Witteles RM, Fisher GA, Srinivas S. Ann Oncol. 2008; 19 (9): 1613-8
• Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. Harshman L, Srinivas S. Onkologie. 2008; 31 (8-9): 432-3
• Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Jonasch E, Stadler WM, Bukowski RM, Hayes TG, Varadhachary A, Malik R, Figlin RA, Srinivas S. Cancer. 2008; 113 (1): 72-7
• The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer. Harshman LC, Li M, Srinivas S. Am J Clin Oncol. 2008; 31 (5): 417-23
• Acute pancreatitis associated with sorafenib. Li M, Srinivas S. South Med J. 2007; 100 (9): 909-11
• Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. Harshman LC, Srinivas S. Expert Rev Anticancer Ther. 2007; 7 (12): 1749-61
• Prostate cancer. Clinical practice guidelines in oncology. Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC. J Natl Compr Canc Netw. 2007; 5 (7): 650-83
• Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D. J Clin Oncol. 2007; 25 (29): 4536-41
• Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. Feldman D, Krishnan A, Moreno J, Swami S, Peehl DM, Srinivas S. Nutr Rev. 2007; 65 (8 Pt 2): S113-5
• Bone related events in high risk prostate cancer. Srinivas S, Colocci N. J Urol. 2006; 176 (6 Pt 2): S50-4
• Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Liu IJ, Lai YH, Espiritu JI, Segall GM, Srinivas S, Nino-Murcia M, Terris MK. Urol Int. 2006; 77 (1): 69-75
• Nonplatinum therapy in advanced bladder cancer. Srinivas S, Colocci N. Expert Rev Anticancer Ther. 2006; 6 (6): 887-94
• Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. Srinivas S, Krishnan AV, Colocci N, Feldman D. Urology. 2006; 67 (5): 1001-6
• Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. King CR, McNeal JE, Gill H, Brooks JD, Srinivas S, Presti JC. Urology. 2006; 67 (6): 1229-34
• A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. Srinivas S, Guardino AE. BJU Int. 2005; 96 (4): 536-9
• A nonplatinum combination in metastatic transitional cell carcinoma. Srinivas S, Guardino AE. Am J Clin Oncol. 2005; 28 (2): 114-8
• Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. Badger J, Kang S, Uzieblo A, Srinivas S. J Clin Oncol. 2005; 23 (28): 7224-5
• Node Positive Bladder Cancer Srinivas S, Freiha F. Arab J Urology. 2005: 3 7-11
• Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily. Murphy JC, Srinivas S, Terris MK. J Androl. 2004 Jul-Aug; 25 (4): 630-4
• Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis. Morgan K, Srinivas S, Freiha F. Urology. 2004; 64 (4): 808-9
• Positron emission tomography in the initial staging of esophageal cancer. Wren SM, Stijns P, Srinivas S. Arch Surg. 2002; 137 (9): 1001-6; discussion 1006-7
• Utility of bone scan post primary therapy in prostate cancer Srinivas S, UroOncology. 2002: 2 37-39
• Management choices in stage I non-seminomatous Germ Cell Tumor Srinivas S, Terris MK. UroOncology. 2001: 1 1-4
• Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Urology. 2001; 57 (1): 127-32
• Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer. Durski JM, Srinivas S, Segall G. Clin Positron Imaging. 2000; 3 (3): 97-105
• High-dose chemotherapy in poor-risk germ-cell tumors. Srinivas S, Oncology (Williston Park). 2000; 14 (10): 1419-23; discussion 1427-30, 1433-4
• Spontaneous pneumothorax in malignancy: a case report and review of the literature. Srinivas S, Varadhachary G. Ann Oncol. 2000; 11 (7): 887-9
• Actinomycin D revisited in testicular cancer. A case report. Srinivas S, Freiha FS. Tumori. 1999 Jan-Feb; 85 (1): 78-9
• Tool support for authoring eligibility criteria for cancer trials. Rubin DL, Gennari JH, Srinivas S, Yuen A, Kaizer H, Musen MA, Silva JS. Proc AMIA Symp. 1999: 369-73
• Methotrexate tolerance in patients with ileal conduits and continent diversions. Srinivas S, Mahalati K, Freiha FS. Cancer. 1998; 82 (6): 1134-6
• Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. J Clin Oncol. 1996; 14 (5): 1617-25
• The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Small EJ, Srinivas S. Cancer. 1995; 76 (8): 1428-34
• Intravenous heparin dosing: patterns and variations in internists' practices. Reilly BM, Raschke R, Srinivas S, Nieman T. J Gen Intern Med. 1993; 8 (10): 536-42
• The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. Ann Intern Med. 1993; 119 (9): 874-81